Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413–1424. https://doi.org/10.1056/NEJMOA2022190/SUPPL_FILE/NEJMOA2022190_DATA-SHARING.PDF

Article  CAS  PubMed  Google Scholar 

Fontes-Carvalho R, Santos-Ferreira D, Raz I, Marx N, Ruschitzka F, Cosentino F (2021) Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. Eur J Prev Cardiol. https://doi.org/10.1093/EURJPC/ZWAB034

Butler J, Packer M, Siddiqi TJ, Böhm M, Brueckmann M, Januzzi JL, Verma S, Gergei I, Iwata T, Wanner C, Ferreira JP, Pocock SJ, Filippatos G, Anker SD, Zannad F (2023) Efficacy of empagliflozin in patients with heart failure across kidney risk categories. J Am Coll Cardiol 81(19):1902–1914. https://doi.org/10.1016/J.JACC.2023.03.390/SUPPL_FILE/MMC1.DOCX

Article  CAS  PubMed  Google Scholar 

Mcmurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008. https://doi.org/10.1056/NEJMOA1911303

Article  CAS  PubMed  Google Scholar 

Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117–128. https://doi.org/10.1056/NEJMOA2030183

Article  CAS  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M et al (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 44(37):3627–3639. https://doi.org/10.1093/EURHEARTJ/EHAD195

Article  CAS  PubMed  Google Scholar 

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail 28(5):e1–e167. https://doi.org/10.1016/J.CARDFAIL.2022.02.010

Article  Google Scholar 

Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, Herrington WG, Hill G, Inker LA, Kazancıoğlu R, Lamb E, Lin P, Madero M, McIntyre N, Morrow K, Roberts G, Sabanayagam D, Schaeffner E, Shlipak M et al (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4):S117–S314. https://doi.org/10.1016/j.kint.2023.10.016

Article  Google Scholar 

Averbuch T, Esfahani M, Khatib R, Kayima J, Miranda JJ, Wadhera RK, Zannad F, Pandey A, Van Spall HGC (2023) Pharmaco-disparities in heart failure: a survey of the affordability of guideline recommended therapy in 10 countries. ESC Hear Fail 10(5):3152–3163. https://doi.org/10.1002/EHF2.14468

Article  Google Scholar 

Pierce JB, Vaduganathan M, Fonarow GC, Ikeaba U, Chiswell K, Butler J, Devore AD, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Linganathan KK, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Greene SJ (2023) Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the get with the guidelines-heart failure registry. JAMA Cardiol 8(7):652–661. https://doi.org/10.1001/JAMACARDIO.2023.1266

Article  PubMed  PubMed Central  Google Scholar 

Rao VN, Murray E, Butler J, Cooper LB, Cox ZL, Fiuzat M, Green JB, Lindenfeld JA, McGuire DK, Nassif ME, O’Brien C, Pagidipati N, Sharma K, Vaduganathan M, Vardeny O, Fonarow GC, Mentz RJ, Greene SJ (2021) In-hospital initiation of sodium glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. J Am Coll Cardiol 78(20):2004. https://doi.org/10.1016/J.JACC.2021.08.064

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen J, Jiang C, Guo M, Zeng Y, Jiang Z, Zhang D, Tu M, Tan X, Yan P, Xu XM, Long Y, Xu Y (2024) Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol 23(1):1–13. https://doi.org/10.1186/S12933-023-02042-9/FIGURES/7

Article  Google Scholar 

Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H et al (2022) The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 28(3):568–574. https://doi.org/10.1038/s41591-021-01659-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cox ZL, Collins SP, Hernandez GA, McRae AT, Davidson BT, Adams K, Aaron M, Cunningham L, Jenkins CA, Lindsell CJ, Harrell FE, Kampe C, Miller KF, Stubblefield WB, Lindenfeld JA (2024) Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol 83(14):1295–1306. https://doi.org/10.1016/J.JACC.2024.02.009

Article  CAS  PubMed  Google Scholar 

Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, van Eck JWM, Heerspink HJL, Voors AA (2020) Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 22(4):713–722. https://doi.org/10.1002/EJHF.1713

Article  CAS  PubMed  Google Scholar 

Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, Von Haehling S, Schumacher U, Möbius-Winkler S, Busch M (2022) Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation 146(4):289–298. https://doi.org/10.1161/CIRCULATIONAHA.122.059038

Article  CAS  PubMed  Google Scholar 

Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, Mattheus M, Zwiener I, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chen Y, Chopra VK, Figtree G, Ge J, Goodman SG, Gotcheva N, Goto S et al (2024) Empagliflozin after acute myocardial infarction. N Engl J Med 390(16):1455–1466. https://doi.org/10.1056/NEJMOA2314051/SUPPL_FILE/NEJMOA2314051_DATA-SHARING.PDF

Article  CAS  PubMed  Google Scholar 

Tavares CAM, Azevedo LCP, Rea-Neto Á, Campos NS, Amendola CP, Kozesinski-Nakatani AC, David-João PG, Lobo SM, Filiponi TC, Almeida GMB, Bergo RR, Guimarães-Júnior MRR, Figueiredo RC, Castro JR, Schuler CJ, Westphal GA, Carioca ACR, Monfradini F, Nieri J et al (2024) Dapagliflozin for critically ill patients with acute organ dysfunction: the DEFENDER randomized clinical trial. JAMA. https://doi.org/10.1001/JAMA.2024.10510

Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, Martinez F, Mukhtar O, Verma S, Chopra V, Buenconsejo J, Langkilde AM, Ambery P, Tang F, Gosch K, Windsor SL, Akin EE, Soares RVP, Moia DDF et al (2021) Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 9(9):586–594. https://doi.org/10.1016/S2213-8587(21)00180-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horby PW, Martin P, Landray J (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Artic Lancet Diabetes Endocrinol. 11:905–919. https://doi.org/10.1016/S2213-8587(23)00253-X

Article  Google Scholar 

James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, Andersen K, Austin D, Arefalk G, Carrick D, Hofmann R, Hoole SP, Jones DA, Lee K, Tygesen H, Johansson PA, Langkilde AM, Ridderstråle W, Parvaresh Rizi E et al (2024) Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid 3(2). https://doi.org/10.1056/evidoa2300286

ESC 365 - Management of acute and residual congestion in patients with acute heart failure by adding dapaglifozin to intravenous loop diuretic therapy-ENDORSE-HF. Accessed June 18, 2024. https://esc365.escardio.org/presentation/280201?query=endorse-hf

Dixit NM, Shah S, Ziaeian B, Fonarow GC, Hsu JJ (2021) Optimizing guideline-directed medical therapies for heart failure with reduced ejection fraction during hospitalization. US Cardiol Rev 15. https://doi.org/10.15420/USC.2020.29

Stolfo D, Lund LH, Benson L, Lindberg F, Ferrannini G, Dahlström U, Sinagra G, Rosano GMC, Savarese G (2023) Real-world use of sodium–glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry. Eur J Heart Fail 25(9):1648–1658. https://doi.org/10.1002/EJHF.2971

Article  CAS  PubMed  Google Scholar 

Hussain A, Ramsey D, Lee M, Mahtta D, Khan MS, Nambi V, Ballantyne CM, Petersen LA, Walker AD, Kayani WT, Butler J, Slipczuk L, Rogers JG, Bozkurt B, Navaneethan SD, Virani SS (2023) Utilization rates of SGLT2 inhibitors among patients with type 2 diabetes, heart failure, and atherosclerotic cardiovascular disease: insights from the department of veterans affairs. JACC Heart Fail 11(8 Pt 1):933–942. https://doi.org/10.1016/J.JCHF.2023.03.024

Article  PubMed  Google Scholar 

Selwyn J, Pichardo-Lowden AR (2023) Managing hospitalized patients taking SGLT2 inhibitors: reducing the risk of euglycemic diabetic ketoacidosis. Diabetol 4(1):86–92. https://doi.org/10.3390/DIABETOLOGY4010010

Article  Google Scholar 

Oskouie S, Pandey A, Sauer AJ, Greene SJ, Mullens W, Khan MS, Quinn KL, Ho JE, Albert NM, Van Spall HGC (2024) From hospital to home: evidence-based care for worsening heart failure. JACC Adv

Nasa P, Chaudhary S, Shrivastava PK, Singh A (2021) Euglycemic diabetic ketoacidosis: a missed diagnosis. World J Diabetes 12(5):514.